Page 301 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

280 PART III Therapeutic Modalities for the Cancer Patient

311. Ebos JM, Lee CR, Cruz-Munoz W, et al.: Accelerated metastasis 332. Baylin SB, Herman JG: DNA hypermethylation in tumorigenesis:
after short-term treatment with a potent inhibitor of tumor angio- epigenetics joins genetics, Trends Genet 16:168-174.
genesis, Cancer Cell 15:232–239, 2009. 333. van Doorn R, Zoutman WH, Dijkman R, et al.: Epigenetic profil-
VetBooks.ir 312. Park JW, Kerbel RS, Kelloff GJ, et al.: Rationale for biomarkers ing of cutaneous T-cell lymphoma: promoter hypermethylation of
and surrogate end points in mechanism-driven oncology drug
multiple tumor suppressor genes including BCL7a, PTPRG, and
p73, J Clin Oncol 23:3886–3896, 2005.
development, Clin Cancer Res 10:3885–3896, 2004.
313. Drevs J, Schneider V: The use of vascular biomarkers and imaging 334. Fujiwara-Igarashi A, Goto-Koshino Y, Mochizuki H, et al.: Inhi-
studies in the early clinical development of anti-tumour agents tar- bition of p16 tumor suppressor gene expression via promoter
geting angiogenesis, J Intern Med 260:517–529, 2006. hypermethylation in canine lymphoid tumor cells, Res Vet Sci 97:
314. Sandri MT, Johansson HA, Zorzino L, et al.: Serum EGFR and 60–63, 2014.
serum HER-2/neu are useful predictive and prognostic markers in 335. Segura-Pacheco B, Trejo-Becerril C, Perez-Cardenas E, et al.: Reac-
metastatic breast cancer patients treated with metronomic chemo- tivation of tumor suppressor genes by the cardiovascular drugs
therapy, Cancer 110:509–517, 2007. hydralazine and procainamide and their potential use in cancer
315. Lindauer A, Di GP, Kanefendt F, et al.: Pharmacokinetic/pharma- therapy, Clin Cancer Res 9:1596–1603, 2003.
codynamic modeling of biomarker response to sunitinib in healthy 336. Tomiyasu H, Goto-Koshino Y, Fujino Y, et al.: Epigenetic regu-
volunteers, Clin Pharmacol Ther 87:601–608, 2010. lation of the ABCB1 gene in drug-sensitive and drug-resistant
316. Marchetti V, Giorgi M, Fioravanti A, et al.: First-line metro- lymphoid tumour cell lines obtained from canine patients, Vet J
nomic chemotherapy in a metastatic model of spontaneous canine 199:103–109, 2014.
tumours: a pilot study, Invest New Drugs 30:1725–1730, 2011. 337. Saleh MH, Wang L, Goldberg MS: Improving cancer immuno-
317. Drevs J, Schneider V: The use of vascular biomarkers and imaging therapy with DNA methyltransferase inhibitors, Cancer Immunol
studies in the early clinical development of anti-tumour agents tar- Immunother 65:787–796, 2016.
geting angiogenesis, J Intern Med 260:517–529, 2006. 338. Sigalotti L, Fratta E, Coral S, et al.: Epigenetic drugs as immuno-
318. Morgan B, Thomas AL, Drevs J, et al.: Dynamic contrast-enhanced modulators for combination therapies in solid tumors, Pharmacol
magnetic resonance imaging as a biomarker for the pharmacologi- Ther 142:339–350, 2014.
cal response of PTK787/ZK 222584, an inhibitor of the vascular 339. Peng D, Kryczek I, Nagarsheth N, et al.: Epigenetic silencing of
endothelial growth factor receptor tyrosine kinases, in patients with TH1–type chemokines shapes tumour immunity and immuno-
advanced colorectal cancer and liver metastases: results from two therapy, Nature 527:249–253, 2015.
phase I studies, J Clin Oncol 21:3955–3964, 2003. 340. Silverman LR, Demakos EP, Peterson BL, et al.: Randomized con-
319. MacLeod AG, Dickinson PJ, LeCouteur RA, et al.: Quantitative trolled trial of azacitidine in patients with the myelodysplastic syn-
assessment of blood volume and permeability in cerebral mass drome: a study of the cancer and leukemia group B, J Clin Oncol
lesions using dynamic contrast-enhanced computed tomography 20:2429–2440, 2002.
in the dog, Acad Radiol 16:1187–1195, 2009. 341. Kantarjian H, Issa JP, Rosenfeld CS, et al.: Decitabine improves
320. Shaked Y, Emmenegger U, Man S, et al.: Optimal biologic dose of patient outcomes in myelodysplastic syndromes: results of a phase
metronomic chemotherapy regimens is associated with maximum III randomized study, Cancer 106:1794–1803, 2006.
antiangiogenic activity, Blood 106:3058–3061, 2005. 342. Issa JP, Gharibyan V, Cortes J, et al.: Phase II study of low-dose
321. Twardowski PW, Smith-Powell L, Carroll M, et al.: Biologic mark- decitabine in patients with chronic myelogenous leukemia resistant
ers of angiogenesis: circulating endothelial cells in patients with to imatinib mesylate, J Clin Oncol 23:3948–3956, 2005.
advanced malignancies treated on phase I protocol with metro- 343. Cashen AF, Schiller GJ, O’Donnell MR, et al.: Multicenter,
nomic chemotherapy and celecoxib, Cancer Invest 26:53–59, 2008. phase II study of decitabine for the first-line treatment of
322. Bertolini F, Mancuso P, Shaked Y, et al.: Molecular and cellular older patients with acute myeloid leukemia, J Clin Oncol 28:
biomarkers for angiogenesis in clinical oncology, Drug Discov Today 556–561, 2010.
12:806–812, 2007. 344. Aparicio A, Eads CA, Leong LA, et al.: Phase I trial of continu-
323. Bernabe LF, Portela R, Nguyen S, et al.: Evaluation of the adverse ous infusion 5-aza-2’-deoxycytidine, Cancer Chemother Pharmacol
event profile and pharmacodynamics of toceranib phosphate 51:231–239, 2003.
administered to dogs with solid tumors at doses below the maxi- 345. Momparler RL, Bouffard DY, Momparler LF, et al.: Pilot phase
mum tolerated dose, BMC Vet Res 9:190, 2013. I-II study on 5-aza-2’-deoxycytidine (Decitabine) in patients with
324. Robinson ES, Khankin EV, Karumanchi SA, et al.: Hypertension metastatic lung cancer, Anticancer Drugs 8:358–368, 1997.
induced by VEGF signaling pathway inhibition: mechanisms and 346. Linnekamp JF, Butter R, Spijker R, et al.: Clinical and biologi-
potential use as a biomarker, Semin Nephrol 30:591–601, 2010. cal effects of demethylating agents on solid tumours - a systematic
325. Brueckner B, Lyko F: DNA methyltransferase inhibitors: old and review, Cancer Treat Rev 54:10–23, 2017.
new drugs for an epigenetic cancer therapy, Trends Pharmacol Sci 347. Pohlmann P, DiLeone LP, Cancella AI, et al.: Phase II trial of
25:551–554, 2004. cisplatin plus decitabine, a new DNA hypomethylating agent, in
326. Herman JG, Baylin SB: Gene silencing in cancer in asso- patients with advanced squamous cell carcinoma of the cervix, Am
ciation with promoter hypermethylation, N Engl J Med 349: J Clin Oncol 25:496–501, 2002.
2042–2054, 2003. 348. Villar-Garea A, Fraga MF, Espada J, et al.: Procaine is a DNA-
327. Szyf M: DNA methylation and cancer therapy, Drug Resist Updat demethylating agent with growth-inhibitory effects in human can-
6:341–353, 2003. cer cells, Cancer Res 63:4984–4989, 2003.
328. Pelham JT, Irwin PJ, Kay PH: Genomic hypomethylation in neo- 349. Zambrano P, Segura-Pacheco B, Perez-Cardenas E, et al.: A phase
plastic cells from dogs with malignant lymphoproliferative disor- I study of hydralazine to demethylate and reactivate the expression
ders, Res Vet Sci 74:101–104, 2003. of tumor suppressor genes, BMC Cancer 5:44, 2005.
329. Ehrlich M: DNA methylation in cancer: too much, but also too 350. Candelaria M, Herrera A, Labardini J, et al.: Hydralazine and
little, Oncogene 21:5400–5413, 2002. magnesium valproate as epigenetic treatment for myelodysplas-
330. Gaudet F, Hodgson JG, Eden A, et al.: Induction of tumors in tic syndrome. Preliminary results of a phase-II trial, Ann Hematol
mice by genomic hypomethylation, Science 300:489–492, 2003. 90:379–387, 2011.
331. Catto JW, Azzouzi AR, Rehman I, et al.: Promoter hypermeth- 351. Espinoza-Zamora JR, Labardini-Mendez J, Sosa-Espinoza A,
ylation is associated with tumor location, stage, and subsequent et al.: Efficacy of hydralazine and valproate in cutaneous T-cell
progression in transitional cell carcinoma, J Clin Oncol 23: lymphoma, a phase II study, Expert Opin Investig Drugs 26:
2903–2910, 2005. 481–487.